Alumis (ALMS) Preferred Stock Liabilities (2023 - 2024)
Alumis' (ALMS) quarterly Preferred Stock Liabilities came in at $639.2 million in Q2 2024, up 86.28% year-on-year from $343.2 million in Q3 2023, and up 28.99% on a QoQ basis from $495.6 million in Q1 2024.
Alumis (ALMS) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Alumis (ALMS) has 2 years of Preferred Stock Liabilities data on file, last reported at $639.2 million in Q2 2024.
- On a quarterly basis, Preferred Stock Liabilities rose 86.28% year-over-year to $639.2 million in Q2 2024; TTM through Jun 2024 was $639.2 million, a 86.28% increase from a year earlier, with the FY2023 full-year figure at $375.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2024 stood at $639.2 million, up from $495.6 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for ALMS reached as high as $639.2 million in Q2 2024 and fell as low as $343.2 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alumis | 2.41 Bn | 2.10 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 639.24 Mn |
| Mar 31, 2024 | 495.58 Mn |
| Dec 31, 2023 | 375.37 Mn |
| Sep 30, 2023 | 343.15 Mn |
| Jun 30, 2023 | 343.15 Mn |